-
公开(公告)号：EP1080095A1
公开(公告)日：2001-03-07
申请号：EP99907332.3
申请日：1999-03-11
发明人： MOLLER, Niels, Peter, Hundahl , ANDERSEN, Henrik, Sune , IVERSEN, Lars, Fogh , OLSEN, Ole, Hvilsted , BRANNER, Sven , HOLSWORTH, Daniel, Dale , BAKIR, Farid , JUDGE, Luke, Milburn , AXE, Frank, Urban , JONES, Todd, Kevin , RIPKA, Wiliam, Charles , GE, Yu , UYEDA, Roy, Teruyuki
IPC分类号： C07D513/04 , C07D333/62 , C07D497/04 , C07D209/18 , A61K31/38 , A61K31/395
摘要： The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPases) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.
-
公开(公告)号：EP1781699A1
公开(公告)日：2007-05-09
申请号：EP05776112.4
申请日：2005-08-16
申请人： NOVO NORDISK A/S
IPC分类号： C07K14/705 , C07K14/715 , C07K16/28 , C07D251/12
CPC分类号： C07K14/7151
摘要： Described are compounds useful for trimerising chemical entities, methods of trimerising chemical entities, and trimerised entities. In one aspect, the entities are peptides.
-
公开(公告)号：EP1677819A1
公开(公告)日：2006-07-12
申请号：EP04762903.5
申请日：2004-10-08
申请人： NOVO NORDISK A/S
CPC分类号： A61K38/27 , C07C237/20 , C07C237/22 , C07C323/60 , C07K14/61
摘要： Sustained release formulations comprising molecules modified so as to have a reduced clearance are provided.
-
公开(公告)号：EP3630805A1
公开(公告)日：2020-04-08
申请号：EP18730247.6
申请日：2018-05-23
申请人： Novo Nordisk A/S
发明人： GAO, Xiang , ZHANG, Xujia , GUAN, Hongtao , THOGERSEN, Henning , SASS-ORUM, Kristian , IVERSEN, Lars, Fogh , NORGAARD, Per , JORGENSEN, Sebastian, Beck , HANSEN, Kristian, Tage , WANG, Yi , FRIEBOES, Kilian, Waldemar, Conde , WIECZOREK, Birgit
IPC分类号： C07K14/50 , A61K38/19 , C07K14/475 , G01N33/68
-
公开(公告)号：EP3463412A1
公开(公告)日：2019-04-10
申请号：EP17727834.8
申请日：2017-05-24
申请人： Novo Nordisk A/S
发明人： ZHANG, Xujia , GAO, Xiang , GUAN, Hongtao , THØGERSEN, Henning , SASS-ØRUM, Kristian , IVERSEN, Lars, Fogh , NØRGAARD, Per , JØRGENSEN, Sebastian, Beck , HANSEN, Kristian, Tage , WANG, Yi
IPC分类号： A61K38/00 , A61K38/27 , C07K14/475
-
公开(公告)号：EP1805216A2
公开(公告)日：2007-07-11
申请号：EP05797317.4
申请日：2005-10-18
申请人： NOVO NORDISK A/S
IPC分类号： C07K14/61
摘要： Compounds of formula (I) wherein GH represent a radical derived from a growth hormone compound by removal of one hydrogen atom from the N-terminal amino group; X represents oxygen or two hydrogen atoms; Z represents a bond, alkylene, arylene, heteroarylene, -CH2-O-(CH2)1-10-, -CH2-O- (C6H4)-, or combinations thereof; and Y represents a radical selected from (II), (III), (IV), and (V), are provided together with methods for making said compounds. The compounds are useful in therapy.
摘要翻译： 式（I）化合物，其中GH表示通过从N-末端氨基除去一个氢原子而衍生自生长激素化合物的基团; X代表氧或两个氢原子; Z表示键，亚烷基，亚芳基，杂亚芳基，-CH 2 -O-（CH 2）1-10 - ， - CH 2 -O-（C 6 H 4） - 或其组合; Y代表选自（II），（III），（IV）和（V）的基团，与制备所述化合物的方法一起提供。 这些化合物可用于治疗。
-
公开(公告)号：EP1781791A2
公开(公告)日：2007-05-09
申请号：EP05784675.0
申请日：2005-08-16
申请人： NOVO NORDISK A/S
发明人： BLUME, Niels, T861 Beijing Riviera , SU, Jing , HAN, Ju, Room 1-1002 building No. 3 , IVERSEN, Lars, Fogh
IPC分类号： C12N15/62 , C07K14/805
CPC分类号： C07K14/805
摘要： Fusion proteins comprising a first protein fused to hemopexin are provided. said fusion proteins exhibit an increased circulation time.
-
公开(公告)号：EP1740701A1
公开(公告)日：2007-01-10
申请号：EP05731875.0
申请日：2005-04-14
申请人： NOVO NORDISK A/S
CPC分类号： C12N15/62 , C07K2319/31
摘要： Fusion protein comprising a protein to be fused, e.g. a therapeutic protein fused to the C-terminal of osteogenic growth peptide (OGP). The fusion proteins have a prolonged circulation time.
-
公开(公告)号：EP1080095B1
公开(公告)日：2005-11-02
申请号：EP99907332.3
申请日：1999-03-11
发明人： MOLLER, Niels, Peter, Hundahl , ANDERSEN, Henrik, Sune , IVERSEN, Lars, Fogh , OLSEN, Ole, Hvilsted , BRANNER, Sven , HOLSWORTH, Daniel, Dale , BAKIR, Farid , JUDGE, Luke, Milburn , AXE, Frank, Urban , JONES, Todd, Kevin , RIPKA, Wiliam, Charles , GE, Yu , UYEDA, Roy, Teruyuki
IPC分类号： C07D513/04 , C07D333/62 , C07D497/04 , C07D209/18 , A61K31/38 , A61K31/395
摘要： The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPases) such as PTP1B, CD45, SHP-1, SHP-2, PTP alpha , LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.017 秒)
